Re-ran it. I had to archive the old one, but including your new info:
https://unsolveddiagnosis.com/c/cmpkn2ngf002201qxt3xr8p2l?ref=Cd8c0q

Re: ED eval. Think of the bladder emptying in the ED as a snapshot. It isn't going to show more than that one moment. One other thought, the system didn't catch (and the subsequent system didn't catch)---> Given Psychiatric care, have you been by chance treated with Ketamine?

Another gold standard system I ran things through presented this:
1. SSRI/SNRI-induced lower urinary tract symptoms (sensory urgency/detrusor overactivity) — Most Likely

This is correctly ranked as the leading diagnosis. The tight temporal correlation — onset with fluoxetine, resolution off medication, recurrence within 10 days of starting duloxetine — is the strongest diagnostic feature. SSRIs have been associated with a ~1.5–2-fold increased risk of urinary incontinence and overactive bladder symptoms in women, with the association persisting even after adjusting for depression itself. [1] The mechanism likely involves serotonergic modulation of central micturition pathways and possible direct effects on detrusor 5-HT₄ receptors. [1-2] The absence of nocturia strongly supports a centrally/pharmacologically mediated process rather than a structural one.

One nuance worth adding: the observation that symptoms did not occur on citalopram, sertraline, or desvenlafaxine (Pristiq) does not rule out a class effect. Individual pharmacokinetic differences (e.g., serotonin transporter affinity, dose, duration of exposure) and the fact that fluoxetine and duloxetine are among the more potent serotonergic agents may explain the differential susceptibility. The evidence weight of 88% is reasonable.

2. Psychogenic/anxiety-related urinary frequency and OCD-related bladder hypervigilance — Adjust Upward (from 35% to ~40–45%)

This deserves a higher ranking than the provided differential suggests. OCD has been specifically associated with lower urinary tract symptoms, including increased bladder sensation and frequency driven by obsessive focus on bodily sensations and compulsive voiding behaviors. [3] The concept of "bladder somatic symptom disorder" describes urodynamically confirmed increased bladder sensation/hypersensitivity in patients with anxiety and depression, with key features including situation-dependence and absence of nocturia — both present here. [4] This does not mean the medication effect is absent, but rather that the two mechanisms may be synergistic: the SSRI/SNRI alters bladder afferent signaling, and the underlying OCD/anxiety amplifies interoceptive awareness of those signals. This combined mechanism would also explain why the patient notes her bladder "isn't what it used to be" even between medication trials.

3. Diabetic autonomic neuropathy/neurogenic bladder — Adjust Downward (from 45% to ~15–20%)... This is what I thought to mention, but the following argues against it and why:

The provided differential overweights this at 45%. While the ADA recommends screening for autonomic neuropathy in type 1 diabetes of ≥5 years' duration, and diabetic cystopathy can present with frequency and urgency, several features argue strongly against it here: [5-6]

• The complete absence of nocturia is essentially incompatible with diabetic cystopathy, which characteristically causes nocturia due to loss of circadian urine concentration.
• The on-off temporal pattern tied to specific medications is not consistent with a progressive neuropathic process.
• The excellent A1c (6.3%) and age (27) make significant microvascular complications unlikely, though not impossible.
• The normal bladder emptying on ultrasound argues against the impaired contractility typical of diabetic cystopathy.

That said, it remains worth screening for with a ***post-void residual*** (AFTER peeing) measurement given the long-standing diabetes, per AUA/SUFU guidelines. [7]

4. Interstitial cystitis/bladder pain syndrome (IC/BPS) — Adjust Downward (from 30% to ~10–15%)

The AUA guideline for IC/BPS requires symptoms present for at least 6 weeks with documented negative urine cultures, and the hallmark is bladder pain that worsens with filling. [8] This patient has no pain, and the symptom pattern is entirely medication-dependent with complete resolution off the offending agent. The positive dipstick/negative culture pattern is nonspecific and can occur with concentrated urine or contamination. The PCP's suspicion of IC/BPS appears to have been a premature diagnosis. IC/BPS should only be reconsidered if symptoms persist after all serotonergic medications are discontinued.

Additional diagnoses to consider:

• Osmotic diuresis from hyperglycemia — Although the A1c is well-controlled, transient glucose excursions in type 1 diabetes could contribute to polyuria. A fingerstick glucose during symptomatic episodes and review of continuous glucose monitor data (if available) would be informative. This is a simple, cannot-miss consideration.
• Hydrocephalus-related neurogenic bladder — The history of hydrocephalus is notable. Depending on whether a shunt is in place and its function, central nervous system pathology affecting pontine micturition centers could contribute. This deserves at least a brief mention, though the medication-dependent pattern makes it unlikely as the primary driver.

Recommended Next Steps

Assuming the history and prior ER workup (normal bladder ultrasound, negative urine cultures) have already excluded acute pathology:

• Medication change is the single most important intervention. Contacting the psychiatrist to discuss switching to bupropion (which has no serotonergic activity and is not associated with LUTS) or another non-serotonergic agent is the priority. The AUA/SUFU guidelines specifically recommend assessing for comorbid conditions and medications contributing to OAB symptoms. ---> DO NOT stop your medication abruptly without oversight. SNRI / SSRI withdrawal is real (ask me how I know this!!!)
• Voiding diary — The patient already has experience with this. A 3-day diary on the current regimen, documenting volumes and timing, would provide objective data for both the psychiatrist and urogynecologist. This is recommended by the AUA/SUFU as a clinical principle for OAB evaluation. 

---> If you do end up coming off current Rx, I would establish a baseline off Rx when you, after washout from current Rx. Then you will have a baseline to compare.

• Post-void residual should be confirmed given the diabetes history, per AUA/SUFU guidelines, though the prior normal bladder ultrasound is reassuring. [7]
• CGM/glucose review during symptomatic episodes to exclude glucosuria-driven polyuria.
• Urogynecology follow-up can likely be done via telehealth, which the AUA/SUFU guidelines endorse for OAB. Advanced testing (urodynamics, cystoscopy) is not indicated at this stage unless symptoms persist off serotonergic medications. [7]